• Research Interests

  • Nicole Bernal, MD, FACS – Diagnosis and treatment of burns, burn health outcomes 
  • Alfredo Cordova, MD – Skin substitutes, robotic innovation, telehealth, hernias
  • Meihong Deng, MD – Sepsis, innate immunity, TLR9 DNA sensing pathway, cGAS-STING DNA sensing pathway, fibroblastic reticular cell biology
  • Daniel Eiferman, MD – Healthcare quality, spinal cord injury, opioid inpatient management, abdominal wall reconstruction, lymphedema
  • Alex Helkin, MD – Social determinants of health, medical education, burn health outcomes
  • David Lindsey, MD – Medical education, residency training
  • Carrie Sims, MD – Novel resuscitative strategies, geriatric trauma, sepsis, NADH biology, domestic and intimate partner violence, gun violence
  • Brett Tracy, MD – Neurological outcomes research, gun violence, resident education, biostatistical programs, frailty, multicenter trials
  • Wendy Wahl, MD – Complications and outcomes in the ICU, geriatric trauma patients, sepsis, anticoagulation 
  • Brian Weiss, MD – Decision making in the ICU, thoracic trauma, utilization of imaging modalities, antibiotic strategies 
  • Jon Wisler, MD – Sepsis, clinical trials, immune dysregulation, necrotizing soft tissue infections, health outcomes
  • Andrew Young, MD – Machine learning, predictive analysis, geriatric falls, blood cerebral vascular injuries, failure to rescue, trauma data systems

  If you are interested in collaborating with a faculty member, please reach out to Holly Baselice.

• Research Programs

  • Epigenetic Regulation and DNA Methylation in Circulating Microvesicles during Sepsis PI: Wisler
  • Role of Toll-like Receptor 9 in Fibroblastic Reticular Cell-based Therapy for Intraabdominal Sepsis PI: Deng

Clinical Trials

• Trauma/Hemorrhagic Shock

  • Evaluation of the Clinical Performance of the Quantra® System with the QStat® Cartridge in Trauma and Liver Transplantation PI: Flores/Wisler
  • Ohio State University TRACK SCI Registry PI: Farhadi/Eiferman

• Coagulation

  • An Open-Label, Randomized, Active Controlled, Multi-Centre Phase 3 Study to Evaluate the Safety and Efficacy of Danaparoid vs Argatroban in Treatment of Subjects with Acute HIT (HITSOVA study) PI: Wisler
  • Prospective, Open-Label Study of Andexanet Alfa in Patients Receiving a Factor Xa Inhibitor Who Require Urgent Surgery (ANNEXA-S) PI: Wisler

• Antimicrobials

  • A Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy and Safety of a Single Dose of Exebacase in Adult Patients Receiving Standard-of-Care Antibiotics for the Treatment of Staphylococcus aureus Bloodstream Infections (Bacteremia), Including Right-Sided Infective Endocarditis PI: Wisler

• Burn/Skin Grafting

  • A Randomized trial of Enteral Glutamine to Minimize Thermal Injury PI: Wisler
  • A Prospective Multicenter Randomized Controlled Clinical Study to Investigate the Safety and Effectiveness of the RECELL System Combined with Meshed Autograft for Reduction of Donor Skin Harvesting in Soft Tissue Reconstruction PI: Cordova
  • Vitamin C in Thermal Injury: The VICTORY Pilot Trial PI: Wisler
  • Use of NexoBrid for Treatment of Acute deep partial and full thickness Burn Injuries PI: Bernal
  • PolyNovo BTM PI: Bernal

• Wound Healing

  • Hydromechanical Cleansing With V.A.C. VeraFlo Cleanse Choice™ Dressing and NPWTi-d vs. Collagenase Ointment in the Management of Pressure Ulcers/Injuries (Accelerate Trial) PI: Wisler

• Traumatic Brain Injury (TBI)

  • Hyperbaric Oxygen Brain Injury Treatment (HOBIT): A Multicenter, Randomized, Prospective Phase II Adaptive Clinical Trial Evaluating the Most Effective Hyperoxia Treatment Paradigm for Severe TBI PI: Mainali/Wisler
  • Brain Oxygen Optimiization in Severe Traumatic Brain Injury - Phase 3): A multicenter, randomized, blinded-endpoint, comparative effectiveness study of goal-directed critical care based upon monitoring of brain tissue oxygen and intracranial pressure versus monitoring of intracranial pressure along in patients with severe traumatic brain injury. PI: Mainali/Wisler

• Critical Care/Rehab

  • A Phase 2A, Randomized, Double-Blind, Placebo-Controlled Study of Intravenous FDY-5301 for the prevention and treatment of muscle wasting and weakness in ICU patients PI: Wisler

• Clinical trials group

  Jonathan Wisler, MD, Lead Investigator
  Adara McCarty, Clinical Research Assistant

  Regulatory, Business and Administrative Support provided by OSU’s Clinical Trials Management Organization (CTMO)